VF (4771) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 望隼

VF (4771) reported revenue of NT$334.7 million for Oct 2026, -5.8% year on year and -15.2% from the previous month. Revenue for Jan–Oct 2026 was NT$3.71 billion (+28.2% year on year).

In Oct 2026, it ranked No. 29 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$311 million24/10Nov 2024 NT$228.1 millionDec 2024 NT$222.7 millionJan 2025 NT$256.6 millionFeb 2025 NT$259.4 million25/02Mar 2025 NT$294.6 millionApr 2025 NT$285.3 millionMay 2025 NT$286.2 millionJun 2025 NT$300.9 million25/06Jul 2025 NT$281.7 millionAug 2025 NT$256 millionSep 2025 NT$315.9 millionOct 2025 NT$355.3 million25/10Nov 2025 NT$308 millionDec 2025 NT$287.6 millionJan 2026 NT$368 millionFeb 2026 NT$314.7 million26/02Mar 2026 NT$348.1 millionApr 2026 NT$420.2 millionMay 2026 NT$381 millionJun 2026 NT$394.9 million26/06Jul 2026 NT$314.6 millionAug 2026 NT$436.9 millionSep 2026 NT$394.5 millionOct 2026 NT$334.7 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$334.7 million-5.8%-15.2%
Sep 2026NT$394.5 million+24.9%-9.7%
Aug 2026NT$436.9 million+70.6%+38.9%
Jul 2026NT$314.6 million+11.7%-20.3%
Jun 2026NT$394.9 million+31.3%+3.6%
May 2026NT$381 million+33.1%-9.3%
Apr 2026NT$420.2 million+47.3%+20.7%
Mar 2026NT$348.1 million+18.2%+10.6%
Feb 2026NT$314.7 million+21.3%-14.5%
Jan 2026NT$368 million+43.4%+27.9%
Dec 2025NT$287.6 million+29.2%-6.6%
Nov 2025NT$308 million+35.0%-13.3%
Oct 2025NT$355.3 million+14.3%+12.5%
Sep 2025NT$315.9 million+22.0%+23.4%
Aug 2025NT$256 million+2.3%-9.1%
Jul 2025NT$281.7 million+20.8%-6.4%
Jun 2025NT$300.9 million+37.8%+5.1%
May 2025NT$286.2 million+10.0%+0.3%
Apr 2025NT$285.3 million+13.6%-3.1%
Mar 2025NT$294.6 million+29.7%+13.6%
Feb 2025NT$259.4 million+18.3%+1.1%
Jan 2025NT$256.6 million-20.3%+15.2%
Dec 2024NT$222.7 million-9.4%-2.4%
Nov 2024NT$228.1 million-14.4%-26.7%
Oct 2024NT$311 million+5.6%+20.1%

Jan–Oct 2026 cumulative: NT$3.71 billion (+28.2% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: VF vs PEC / VF vs Lotus Pharm / VF vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16